Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder
December 18, 2019 16:05 ET
|
Minerva Neurosciences, Inc
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpointsMIN-117 was generally well-tolerated with a safety profile comparable to placeboCompany to host conference call at...
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019
November 14, 2019 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
November 04, 2019 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
October 28, 2019 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update for Three Clinical Trials
October 01, 2019 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET
September 26, 2019 16:10 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
September 24, 2019 09:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass. and SOMERSET, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative...
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
August 05, 2019 07:30 ET
|
Minerva Neurosciences, Inc
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive...
Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
July 29, 2019 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
June 24, 2019 07:30 ET
|
Minerva Neurosciences, Inc
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexantKey secondary endpoint,...